Swiniarski H, Wolf S F, Sturmhoefel K, Peterson R L, Dorner A J, O'Toole M
Genetics Institute, One Burtt Road, Andover, Massachusetts 01810, USA.
Clin Immunol. 2000 Mar;94(3):200-11. doi: 10.1006/clim.2000.4836.
The effect of in vivo administration of rmIL-12 on the CTL response to immunization with a weakly immunogenic class I-restricted peptide emulsified in incomplete Freund's adjuvant was investigated. In the absence of IL-12, peptide-specific CTL responses were significantly greater following coimmunization with class I-restricted peptide and T helper cell antigens than following immunization with the class I-restricted peptide alone. IL-12-dependent enhancement of the CTL response to peptide immunization was demonstrated in the presence of, but not in the absence of, coimmunization with T helper cell antigen. These findings indicate that IL-12 enhancement of the CTL response to weak class I-restricted immunogens is T helper cell dependent. Treatment with rmIL-12 also enhanced the CTL response to immunization with cDNA encoding both CTL and T helper cell epitopes. These findings are relevant to the design of vaccines containing tumor-associated class I-restricted peptides currently being tested as an immunotherapy for cancer patients.
研究了体内给予重组人白细胞介素-12(rmIL-12)对用不完全弗氏佐剂乳化的弱免疫原性I类限制性肽免疫后CTL反应的影响。在没有IL-12的情况下,与I类限制性肽和T辅助细胞抗原共同免疫后,肽特异性CTL反应明显大于单独用I类限制性肽免疫后的反应。在与T辅助细胞抗原共同免疫存在但不存在的情况下,均证明了IL-12对肽免疫的CTL反应有依赖性增强。这些发现表明,IL-12对弱I类限制性免疫原的CTL反应增强是T辅助细胞依赖性的。用rmIL-12治疗也增强了对编码CTL和T辅助细胞表位的cDNA免疫的CTL反应。这些发现与目前作为癌症患者免疫疗法正在测试的含有肿瘤相关I类限制性肽的疫苗设计有关。